Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Peritoneal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT02502266
What this trial is testing

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous Adenocarcinoma+12 more
National Cancer Institute (NCI) 582
Testing effectiveness (Phase 2)Study completedNCT00510653
What this trial is testing

Gleevec Study for Patients With Ovarian Cancer

Who this might be right for
Ovarian Cancer
M.D. Anderson Cancer Center 73
Testing effectiveness (Phase 2)WithdrawnNCT05672095
What this trial is testing

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
City of Hope Medical Center
Testing effectiveness (Phase 2)WithdrawnNCT01131039
What this trial is testing

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube NeoplasmsOvarian CancerPrimary Peritoneal
Emory University
Testing effectiveness (Phase 2)Study completedNCT02948075
What this trial is testing

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Who this might be right for
Ovarian Cancer
NewVac LLC 31
Large-scale testing (Phase 3)Ended earlyNCT04729387
What this trial is testing

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Who this might be right for
Ovarian Cancer
Novartis Pharmaceuticals 358
Testing effectiveness (Phase 2)Study completedNCT00004081
What this trial is testing

Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal Cavity Cancer
Beth Israel Deaconess Medical Center 30
Testing effectiveness (Phase 2)UnknownNCT05407584
What this trial is testing

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Who this might be right for
PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Yonsei University 56
Early research (Phase 1)UnknownNCT03283943
What this trial is testing

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
British Columbia Cancer Agency 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT02101775
What this trial is testing

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid Adenocarcinoma+9 more
National Cancer Institute (NCI) 124
Testing effectiveness (Phase 2)Ended earlyNCT02012192
What this trial is testing

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Medical University Innsbruck 133
Testing effectiveness (Phase 2)Study completedNCT06173037
What this trial is testing

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
RemeGen Co., Ltd. 43
Testing effectiveness (Phase 2)Looking for participantsNCT05538091
What this trial is testing

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPARP Inhibitor+1 more
Ronald Buckanovich 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04781088
What this trial is testing

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+4 more
Floor Backes, MD 38
Early research (Phase 1)Study completedNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT06028932
What this trial is testing

Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Who this might be right for
Ovarian Carcinoma
Yale University 20
Testing effectiveness (Phase 2)Ended earlyNCT00023907
What this trial is testing

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Ended earlyNCT00004037
What this trial is testing

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT03314740
What this trial is testing

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

Who this might be right for
Ovarian Neoplasms
Mario Negri Institute for Pharmacological Research 123
Testing effectiveness (Phase 2)Study completedNCT03093155
What this trial is testing

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Yale University 78
Next Page